Heart transplant recipient patient with COVID‐19 treated with tocilizumab | Zendy

Mattioli Massimo | Zendy; Fustini Elisa | Zendy; Gennarini Silvia | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Heart transplant recipient patient with COVID‐19 treated with tocilizumab

Author(s) -

Mattioli Massimo,

Fustini Elisa,

Gennarini Silvia

Publication year - 2020

Publication title -

transplant infectious disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.69

H-Index - 67

eISSN - 1399-3062

pISSN - 1398-2273

DOI - 10.1111/tid.13380

Subject(s) - tocilizumab , medicine , rash , covid-19 , pneumonia , pulmonary function testing , adverse effect , dry cough , dermatology , surgery , disease , infectious disease (medical specialty)

A heart transplant 62‐year‐old patient referred for coronavirus‐19 disease (COVID‐19) pneumonia. At admission, he was febrile, tachypnoeic, and mild hypoxic with dry cough; during hospitalization, a diffuse morbilliform skin rash appeared. He was treated with tocilizumab with symptoms improvement, without a complete pulmonary function recovery. Skin rash, highly suggestive for COVID‐19 cutaneous involvement, persisted for ten days despite tocilizumab administration.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research